Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360287 | 0.79 | SIGMAR1 (0.52) | SIGMAR1ADRA2AOPRM1 | |
| SCHEMBL736557 | 0.79 | SIGMAR1 (0.52) | SIGMAR1ADRA2AOPRM1 | |
| SCHEMBL12175506 | 0.76 | PRCP (0.47) | — | |
| SCHEMBL24203981 | 0.75 | MEN1 (0.37) | SIGMAR1ADRA2AOPRM1OPRK1EBP | |
| SCHEMBL30376318 | 0.75 | MEN1 (0.37) | SIGMAR1ADRA2AOPRM1OPRK1EBP | |
| SCHEMBL29190477 | 0.72 | TMEM97 (0.41) | SIGMAR1ADRA2A | |
| SCHEMBL12622887 | 0.71 | TMEM97 (0.40) | SIGMAR1ADRA2AOPRM1OPRK1 | |
| SCHEMBL3406036 | 0.70 | SIGMAR1 (0.37) | SIGMAR1ADRA2AOPRM1OPRK1 | |
| SCHEMBL11864088 | 0.69 | SIGMAR1 (0.54) | SIGMAR1ADRA2AOPRM1OPRK1 | |
| SCHEMBL17027449 | 0.68 | SIGMAR1 (0.36) | SIGMAR1ADRA2AOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107916-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-9828385-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3107916-A1 | SPIRO-OXAZOLONES | F. Hoffmann-La Roche AG (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-20160355522-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015124541-A1 | SPIRO-OXAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355522-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885ADRA2A 41/4885KDM1A 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.